Pietrobono, Silvia http://orcid.org/0000-0002-5544-7286
Gaudio, Eugenio
Gagliardi, Sinforosa
Zitani, Mariapaola
Carrassa, Laura
Migliorini, Francesca
Petricci, Elena
Manetti, Fabrizio
Makukhin, Nikolai
Bond, Adam G. http://orcid.org/0000-0002-1271-1032
Paradise, Brooke D.
Ciulli, Alessio
Fernandez-Zapico, Martin E.
Bertoni, Francesco
Stecca, Barbara http://orcid.org/0000-0003-1197-1622
Article History
Received: 4 December 2020
Revised: 22 March 2021
Accepted: 7 April 2021
First Online: 6 May 2021
Compliance with ethical standards
:
: FB: institutional research funds from Acerta, ADC Therapeutics, Bayer AG, Cellestia, CTI Life Sciences, EMD Serono, Helsinn, ImmunoGen, Menarini Ricerche, NEOMED Therapeutics 1, Nordic Nanovector ASA, Oncology Therapeutic Development and PIQUR Therapeutics AG. AC: institutional research funds from Amphista therapeutics, Boehringer Ingelheim, Eisai Inc., Nurix Inc., and Ono Pharma; scientific founder, shareholder, non-executive director and consultant of Amphista Therapeutics. The other authors declare no competing interests.